Patent Application
20170188607
The present invention relates to the flavor industry. It concerns more particularly a process for increasing the solubility of flavor ingredients in liquid food and beverages and it also concerns a means of delivering the ingredients.
A flavor and sweet modulating compound: (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one has a solubility limit in water. The use of the compound is contemplated to be used in higher concentration in certain beverages at low pH. Hence it is desirable to improve the solubility or to stabilize the supersaturated state of this compound particularly in aqueous beverages.
Provided herein is a method of making a concentrated solution of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, or a salt or solvate thereof, comprising adding to an aqueous solution:
Further provided herein is an aqueous solution comprising:
For the descriptions herein and the appended claims, the use of “or” means “and/or” unless stated otherwise. Similarly, “comprise,” “comprises,” “comprising” “include,” “includes,” and “including” are interchangeable and not intended to be limiting.
It is to be further understood that where descriptions of various embodiments use the term “comprising,” those skilled in the art would understand that in some specific instances, an embodiment can be alternatively described using language “consisting essentially of” or “consisting of.”
Further provided herein is a method of making a concentrated solution of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, or a salt or solvate thereof comprising:
In another embodiment provided herein is a method comprising:
Further provided herein is a method of making a concentrated solution of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, or a salt or solvate thereof, comprising adding to an aqueous solution:
Further provided herein is an aqueous solution comprising:
In another embodiment, a concentrated solution comprises greater than 9 ppm of the (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, or its salt or solvate thereof, by weight of the total weight of the concentrated solution at a pH of less than or equal to 4.
In another embodiment, a concentrated solution comprises from about 1 ppm to about 100 ppm by weight, of the total weight of the solution, (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, or a salt or solvate thereof, at a pH of less than or equal to 4 and a temperature of 3° C. at 12 weeks.
In another embodiment, a concentrated solution comprises from about 1 ppm to about 45 ppm by weight, of the total weight of the solution, (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, or a salt or solvate thereof, at a pH of less than or equal to 4 and a temperature of 3° C. at 12 weeks.
In another embodiment, a concentrated solution comprises from about 9 ppm to about 35 ppm by weight, of the total weight of the solution, (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, or a salt or solvate thereof, at a pH of less than or equal to 4 and at a temperature of 3° C. or 20° C. at 12 weeks.
In another embodiment, a concentrated solution comprises about 15 ppm to about 35 ppm, more particularly from 15 to about 30 ppm, even more particularly at about 18 ppm, by weight, of the total weight of the solution, (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, or a salt or solvate thereof, at a pH of less than or equal to 4 and at a temperature of 3° C. or 20° C. at 12 weeks.
In another embodiment, the concentration of the (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, or its salt or solvate thereof, in the concentrated solution comprising the food polymer is about 1 ppm up to about 40 ppm, particularly from about 9 ppm to 35 ppm; particularly from about 15 ppm to about 30 ppm by weight of the total weight of the concentrated solution, at a pH of less than or equal to 4.
In a further embodiment, the concentration of the (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, or its salt or solvate thereof, in the concentrated solution comprising the food polymer is about from 15 ppm up to about 100 ppm, more particularly from about 30 up to about 100 ppm, more particularly from about 15 ppm to about 30 ppm, more particularly at about 18 ppm, by weight of the total weight of the concentrated solution, at a pH of less than or equal to 4.
The concentrated solution and syrups provided herein are provided in a solution or syrup that has a pH of less than or equal to 4, particularly from about 1.5 to 3, more particularly from about 2 to about 3, and more particularly at about 2.8.
The acids provided here include but are not limited to organic, food grade acids such as carboxylic acids such as citric acid, lactic acid, malic acid, tartric acid, and their corresponding salts, as well as inorganic, food grade acids, particularly phosphoric acid, and its derivatives and their corresponding salts.
In some embodiments, the solutions or syrups provided herein comprise citrate.
In one embodiment provided herein the food grade polymer is selected from the group consisting of polyvinylpyrrolidone, hydroxypropylmethyl cellulose, hydroxypropylcellulose, carboxymethylcellulose, cellulose derivatives, gums, alginates, pectins, agar, Carrageenan, starch and starch derivatives. Particularly the food grade polymer is selected from the group polyvinylpyrrolidone, hydroxypropylmethyl cellulose (HPMC), hydroxypropylcellulose, and carboxymethylcellulose, more particularly the polymer is HPMC and carboxymethylcellulose. In a particular embodiment the gum is selected from the group consisting of xanthan, acacia, arabic, guar, gellan and carrageenan.
In another embodiment, the re-crystallization of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, or a salt or solvate in a concentrated solution or syrup is inhibited by increasing the viscosity of the solution.
In another embodiment, the polymer concentration in a concentrated solution of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, or a salt or solvate thereof ranges from about 1 ppm to about 200,000 ppm, more particularly from 1 ppm to about 100,000 ppm, more particularly from about 1 ppm to about 50,000 ppm, even more particularly about 1 to 10,000 ppm and even more particularly from about 1 ppm to about 1,000 ppm. In another embodiment, the polymer concentration is from about 1,000 up to about 200,000 ppm.
The ratio of food grade polymer with respect to (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, or a salt or solvate thereof, either in a concentrated solution or as powder blend with the salt or as spray dried mixture with the salt ranges from 0.1 to 1 to 20 to 1, more particularly from about 0.5 to 1 to 20 to 1, expressed in weight percent. Particularly ratios range from 0.1:1 to 3:1, more particularly from 0.5:1 to 3:1, even more particularly from about 1:1 to 10:1 even more particularly from 2:1 to about 10:1.
In another embodiment provided herein the sweetener is selected from the group consisting of common saccharide sweeteners, e.g., sucrose, fructose (e.g., D-fructose), glucose (e.g., D-glucose); sweetener compositions comprising natural sugars, such as corn syrup (including high fructose corn syrup) or other syrups or sweetener concentrates derived from natural fruit and vegetable sources. More particularly, the sweetener is high fructose corn syrup.
In one embodiment, the sweetener is provided in an aqueous solution in an amount sufficient to form a syrup. Particularly the sweetener is provided in a syrup in an amount, by weight of the total weight of the syrup of from about 18% to about 72%, particularly from about 40% to about 50%, more particularly at 45%.
The solutions provided herein may include further optional ingredients for example but not limited to mono-, oligo- and polysaccharides such as, but not limited to maltodextrin.
Other optional ingredients in the solutions are contemplated such as flavors and flavor compositions.
The methods provided herein allow for a substantial increase in the solubility of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one. Further, the methods provided herein allow for a substantial increase in stability of the solutions, e.g., the prevention of precipitation of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, particularly at high concentrations.
In a further embodiment provided here, beverage products include, without limitation, carbonated soft drinks, including cola, lemon-lime, root beer, heavy citrus (“dew type”), fruit flavored and cream sodas; powdered soft drinks, as well as liquid concentrates such as fountain syrups and cordials; coffee and coffee-based drinks, coffee substitutes and cereal-based beverages; teas, including dry mix products as well as ready-to-drink teas (herbal and tealeaf based); fruit and vegetable juices and juice flavored beverages as well as juice drinks, nectars, concentrates, punches and “ades”; sweetened and flavored waters, both carbonated and still; sport/energy/health drinks; alcoholic beverages plus alcohol-free and other low-alcohol products including beer and malt beverages, cider, and wines (still, sparkling, fortified wines and wine coolers); other beverages processed with heating (infusions, pasteurization, ultra high temperature, ohmic heating or commercial aseptic sterilization) and hot-filled packaging; and cold-filled products made through filtration or other preservation techniques.
In one embodiment, the concentrated solutions and syrups provided herein are ideally suited to be diluted further for example into a beverage to supply for example (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, or a salt or solvate thereof, at less than 7 ppm to about 0.1 ppm by weight, of the total weight of the beverage, particularly from about 0.2 to about 6 ppm, more particularly from about 0.5 ppm to about 3 ppm and even more particularly from about 0.5 ppm to about 1 ppm, by weight of the total weight of the solution.
“Salt” refers to a salt of a compound, which possesses the desired pharmacological activity of the parent compound. Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine and the like. Particularly provided herein alkali metal ions are potassium and sodium ions.
“Solvate” means a compound formed by solvation (the combination of solvent molecules with molecules or ions of the solute), or an aggregate that consists of a solute ion or molecule, i.e., a compound of the present invention, with one or more solvent molecules. When water is the solvent, the corresponding solvate is “hydrate”.
The solutions provided herein further provide a reduced sugar beverage.
The below examples are illustrative only and are not meant to limit the claims or embodiments described herein.
A concentrated solution 1 of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one at 0.3% (w/w) (3000 ppm) was prepared in water. pH was adjusted to 11 using NaOH to form (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one sodium salt and obtain an homogeneous solution. Next, a syrup was prepared by mixing an aqueous solution of High Fructose Corn Syrup (HFCS), citric acid and deionized water. The final syrup contained 34% fructose, 0.68% citric acid, 0.1% sodium citrate and 65.22% water, with a pH of 2. An aliquot of solution 1 was diluted 100 times with the syrup to yield a final concentration of 30 ppm of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, i.e. about 18 times above the intrinsic solubility of the compound at 3° C. The sample was kept at 3° C. and the amount of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one was measured by UV spectroscopy as a function of time. The amount of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one was reduced to 28 ppm after 1 week and first crystals were visually observed. After 12 weeks 1.7 ppm of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one remained in solution. See
A concentrated solution 1 of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one at 0.3% (w/w) (3000 ppm) was prepared in water. pH was adjusted to 11 using NaOH to form (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one sodium salt and obtain an homogeneous solution. Next, a syrup was prepared by mixing an aqueous solution of HFCS, citric acid, PVP 55k and deionized water. The final syrup contained 34% fructose, 0.68% citric acid, 0.1% sodium citrate, 0.03% PVP and 65.19% water. An aliquot of solution 1 was diluted 100 times with the syrup to yield a final concentration of 30 ppm of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, i.e. about 18 times above the intrinsic solubility of the compound at 3° C. The sample was kept at 3° C. and the amount of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one was measured by UV spectroscopy as a function of time. The amount of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one was maintained at 30 ppm for 4 weeks, before a slight decrease and appearance of few crystals. After 12 weeks 9.6 ppm of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one remained in solution.
A concentrated solution 1 of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one at 0.3% (w/w) (3000 ppm) was prepared in water. pH was adjusted to 11 using NaOH to form (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one sodium salt and obtain an homogeneous solution. Next, a syrup was prepared by mixing an aqueous solution of HFCS, citric acid, PVP 55k, maltodextrin (18DE) and deionized water. The final syrup contained 34% fructose, 15% maltodextrin, 0.68% citric acid, 0.1% sodium citrate, 0.03% PVP and 65.19% water. An aliquot of solution 1 was diluted 100 times with the syrup to yield a final concentration of 30 ppm of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, i.e. about 18 times above the intrinsic solubility of the compound at 3° C. The sample was kept at 3° C. and the amount of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one was measured by UV spectroscopy as a function of time. The amount of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one was maintained at 30 ppm for 8 weeks, before a slight decrease and appearance of few crystals. After 12 weeks 27.3 ppm of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one remained in solution. See
A concentrated solution 1 of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one at 0.3% (w/w) (3000 ppm) was prepared in water. pH was adjusted to 11 using NaOH to form (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one sodium salt and obtain an homogeneous solution. Next, a syrup was prepared by mixing an aqueous solution of HFCS, citric acid, hydroxypropylmethylcellulose (HPMC, 22 kDa, Sigma) and deionized water. The final syrup contained 34% fructose, 0.68% citric acid, 0.1% sodium citrate, 0.03% HPMC and 65.19% water. An aliquot of solution 1 was diluted 100 times with the syrup to yield a final concentration of 30 ppm of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, i.e. about 18 times above the intrinsic solubility of the compound at 3° C. The sample was kept at 3° C. and the amount of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one was measured by UV spectroscopy as a function of time. The amount of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one was maintained at 30 ppm for 12 weeks. See
A concentrated solution 2 of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one at 1% (w/w) (10000 ppm) was prepared in water. The pH was adjusted to 11 using NaOH to form the (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one sodium salt, and a homogeneous solution was obtained. Next, a syrup was prepared by mixing an aqueous solution of HFCS, citric acid and deionized water. The final syrup contained 43% fructose, 1% citric acid, and 56% water. An aliquot of solution 2 was diluted 100 times with the syrup to yield a final concentration of 100 ppm of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, i.e. about 15 times above the intrinsic solubility of the compound at 20° C. The sample was stirred at 20° C. and crystallization was followed in a Crystalline PV device equipped with CCD cameras. Crystallization started after about 530 minutes.
A concentrated solution 2 of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one at 1% (w/w) (10000 ppm) was prepared in water. The pH was adjusted to 11 using NaOH to form the (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one sodium salt, and a homogeneous solution was obtained. Next, a syrup was prepared by mixing an aqueous solution of HFCS, citric acid, HydroxyPropyl Cellulose (HPC) 100k and deionized water. The final syrup contained 43% fructose, 1% citric acid, 0.05% HPC and 55.95% water. An aliquot of solution 2 was diluted 100 times with the syrup to yield a final concentration of 100 ppm of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, i.e. about 15 times above the intrinsic solubility of the compound at 20° C. The sample was stirred at 20° C. and crystallization was followed in a Crystalline PV device equipped with CCD cameras. First crystals were observed after about 3520 minutes.
A concentrated solution 2 of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one at 1% (w/w) (10000 ppm) was prepared in water. The pH was adjusted to 11 using NaOH to form the (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one sodium salt, and a homogeneous solution was obtained. Next, a citric acid buffer solution was prepared by mixing 50 mM citric acid in deionised water (pH=2.8). An aliquot of solution 2 was diluted 100 times with the buffer solution to yield a final concentration of 100 ppm of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, i.e. about 15 times above the intrinsic solubility of the compound at 20° C. The sample was stirred at 20° C. and crystallization was followed in a Crystalline PV device equipped with CCD cameras. First crystals were observed after about 166 minutes.
A concentrated solution 2 of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one at 1% (w/w) (10000 ppm) was prepared in water. The pH was adjusted to 11 using NaOH to form the (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one sodium salt, and a homogeneous solution was obtained. Next, a citric acid buffer solution was prepared by mixing 50 mM citric acid and carboxymethyl cellulose (CMC) in deionised water (pH=2.8). The final water solution contained 50 mM citric acid and 0.05% CMC. An aliquot of solution 2 was diluted 100 times with the buffer solution to yield a final concentration of 100 ppm of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, i.e. about 15 times above the intrinsic solubility of the compound at 20° C. The sample was stirred at 20° C. and crystallization was followed in a Crystalline PV device equipped with CCD cameras. First crystals were observed after about 466 minutes.
A concentrated solution 2 of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one at 1% (w/w) (10000 ppm) was prepared in water. The pH was adjusted to 11 using NaOH to form the (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one sodium salt, and a homogeneous solution was obtained. Next, a syrup was prepared by mixing an aqueous solution of HFCS, citric acid, HPMC 100k and deionized water. The final syrup contained 43% fructose, 1% citric acid, 0.05% HPMC and 55.95% water. An aliquot of solution 2 was diluted 100 times with the syrup to yield a final concentration of 100 ppm of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, i.e. about 15 times above the intrinsic solubility of the compound at 20° C. The sample was stirred at 20° C. and crystallization was followed in a Crystalline PV device equipped with CCD cameras. No crystallization was observed after seven days.
A concentrated solution 1 of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one at 1% (w/w) (10000 ppm) was prepared in water. pH was adjusted to 11 using NaOH to form (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one sodium salt and obtain an homogeneous solution. Next, a syrup was prepared by mixing an aqueous solution of High Fructose Corn Syrup (HFCS), citric acid, and deionized water. The final syrup contained 45% fructose, 0.68% citric acid, 0.1% sodium citrate, and 54.22% water, with a pH of 2. An aliquot of solution 1 was diluted 555.5 times with the syrup to yield a final concentration of 18 ppm of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, i.e. about 11 times above the intrinsic solubility of the compound at 3° C. The sample was kept at 3° C. and the amount of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one was measured by UV spectroscopy as a function of time. The amount of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one was reduced to 15.8 ppm after 7 weeks and first crystals were visually observed. After 14 weeks 3.6 ppm of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one remained in solution.
A concentrated solution 1 of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one at 1% (w/w) (10000 ppm) was prepared in water. pH was adjusted to 11 using NaOH to form (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one sodium salt and obtain an homogeneous solution. Next, a syrup was prepared by mixing an aqueous solution of HFCS, citric acid, hydroxypropylmethylcellulose (Methocel K99 Food Grade, Dow Chemical) and deionized water. The final syrup contained 45% fructose, 0.68% citric acid, 0.1% sodium citrate, 0.0009% HPMC and 54.2191% water, with a pH of 2. An aliquot of solution 1 was diluted 555.5 times with the syrup to yield a final concentration of 18 ppm of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, i.e. about 11 times above the intrinsic solubility of the compound at 3° C. The sample was kept at 3° C. and the amount of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one was measured by UV spectroscopy as a function of time. The amount of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one was maintained at 18 ppm for 17 weeks. See
A concentrated solution 1 of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one at 1% (w/w) (10000 ppm) was prepared in water. pH was adjusted to 11 using NaOH to form (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one sodium salt and obtain an homogeneous solution. Next, a syrup was prepared by mixing an aqueous solution of HFCS, citric acid, carboxymethylcellulose (CMC, Clear+Stable 30 Easymix Food Grade, Dow Chemical) and deionized water. The final syrup contained 45% fructose, 0.68% citric acid, 0.1% sodium citrate, 0.0009% CMC and 54.2191% water, with a pH of 2. An aliquot of solution 1 was diluted 555.5 times with the syrup to yield a final concentration of 18 ppm of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, i.e. about 11 times above the intrinsic solubility of the compound at 3° C. The sample was kept at 3° C. and the amount of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one was measured by UV spectroscopy as a function of time. The amount of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one was maintained at 18 ppm for 16 weeks. See
A concentrated solution 1 of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one at 1% (w/w) (10000 ppm) was prepared in water. pH was adjusted to 11 using NaOH to form (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one sodium salt and obtain an homogeneous solution. Next, a syrup was prepared by mixing an aqueous solution of High Fructose Corn Syrup (HFCS), citric acid, and deionized water. The final syrup contained 20% fructose, 0.68% citric acid, 0.1% sodium citrate, and 79.22% water, with a pH of 2. An aliquot of solution 1 was diluted 555.5 times with the syrup to yield a final concentration of 18 ppm of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, i.e. about 11 times above the intrinsic solubility of the compound at 3° C. The sample was kept at 3° C. and the amount of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one was measured by UV spectroscopy as a function of time. The amount of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one was reduced to 14 ppm after 3.5 weeks and crystals were visually observed. After 18 weeks 4 ppm of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one remained in solution.
A concentrated solution 1 of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one at 1% (w/w) (10000 ppm) was prepared in water. pH was adjusted to 11 using NaOH to form (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one sodium salt and obtain an homogeneous solution. Next, a syrup was prepared by mixing an aqueous solution of HFCS, citric acid, hydroxypropylmethylcellulose (Methocel K99 Food Grade, Dow Chemical) and deionized water. The final syrup contained 20% fructose, 0.68% citric acid, 0.1% sodium citrate, 0.0009% HPMC and 79.2191% water, with a pH of 2. An aliquot of solution 1 was diluted 555.5 times with the syrup to yield a final concentration of 18 ppm of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one, i.e. about 11 times above the intrinsic solubility of the compound at 3° C. The sample was kept at 3° C. and the amount of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one was measured by UV spectroscopy as a function of time. The amount of (S)-1-(3-(((4-amino-2,2-dioxido-1H-benzo[c][1,2,6]thiadiazin-5-yl)oxy)methyl)piperidin-1-yl)-3-methylbutan-1-one was maintained at 18 ppm for 18 weeks. See
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2015/058623 | 4/22/2015 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 61990849 | May 2014 | US |
